Angiomax Patent Dispute: On-Sale Bar Applies To Distribution Agreement
Executive Summary
Hospira's generic does not infringe The Medicine Company's patented method of making Angiomax, US Federal Circuit finds, but leaves question of whether TMC's distribution agreement covers manufacturing process for the district court to decide.
You may also be interested in...
Does Sale Of Confidential Invention Prevent Its Patenting? US Supreme Court Will Review
Helsinn v. Teva challenges whether inventor's sale of an invention to a third party that must in turn keep the invention secret makes it unpatentable; America Invents Act amended "on-sale" bar provision.
Hospira's Angiomax Generic At Risk As Contract Manufacturing Gets Legal Reprieve
Federal Circuit en banc court reverses panel decision, giving The Medicines Company chance to prove infringement and get Hospira's generic off the market.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.